mapping the effectiveness and risks of glp-1 receptor agonists Author Correction: Emerging Frontiers in GLP-1 Therapeutics:

By targeting the intestine, PAS-LAR can cause or exacerbate diabetes mellitus by strongly inhibiting GLP-1 or GIP secretion

Three semaglutide medications are currently approved by the FDA: Wegovy is approved for weight loss treatment, and can be prescribed to adults and children 12 and older with obesity, as well as some adults with overweight who also have weight-related health problems, such as high blood pressure

Injection site pain or redness is the most common complaint

doi: 10.1161/CIRCULATIONAHA.118.038868 67 CarusoICignarelliASoriceGPNatalicchioAPerriniSLaviolaLet al

Amylin, GIP, glucagon, leptin-related biology, muscle preservation, inflammation, and liver-directed mechanisms may all become part of the treatment landscape

Navas CM, Patel NK, Lacy BE